A number of other analysts have also recently weighed in on the company. Citigroup reissued a buy rating on shares of Epizyme in a research report on Thursday, May 30th. HC Wainwright set a $25.00 price objective on Epizyme and gave the stock a buy rating in a research report on Monday, June 24th. Zacks Investment Research cut Epizyme from a buy rating to a hold rating and set a $15.00 price objective for the company. in a research report on Wednesday, August 14th. Finally, Wedbush reaffirmed an outperform rating and set a $21.00 price target on shares of Epizyme in a research report on Wednesday, June 12th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $18.11.
Epizyme stock opened at $12.86 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.56 and a quick ratio of 10.56. Epizyme has a 1-year low of $5.14 and a 1-year high of $16.59. The business has a fifty day moving average price of $12.96 and a 200-day moving average price of $12.75.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 9th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.02). The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $0.32 million. Epizyme’s quarterly revenue was down 50.8% on a year-over-year basis. During the same period last year, the firm earned ($0.42) earnings per share. Research analysts anticipate that Epizyme will post -2.13 EPS for the current fiscal year.
In other Epizyme news, CEO Robert B. Bazemore sold 2,074 shares of Epizyme stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $12.10, for a total transaction of $25,095.40. Following the completion of the sale, the chief executive officer now owns 87,068 shares of the company’s stock, valued at approximately $1,053,522.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David M. Mott sold 104,944 shares of Epizyme stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total value of $1,372,667.52. Following the sale, the director now directly owns 13,979 shares of the company’s stock, valued at approximately $182,845.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 108,203 shares of company stock valued at $1,412,101. 16.60% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of EPZM. Legal & General Group Plc lifted its holdings in shares of Epizyme by 16.9% in the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,455 shares during the period. Aperio Group LLC acquired a new position in shares of Epizyme in the 2nd quarter valued at about $72,000. Two Sigma Advisers LP acquired a new position in shares of Epizyme in the 4th quarter valued at about $76,000. Exane Derivatives acquired a new position in shares of Epizyme in the 1st quarter valued at about $84,000. Finally, Rockefeller Capital Management L.P. acquired a new position in shares of Epizyme in the 2nd quarter valued at about $88,000. 83.65% of the stock is owned by institutional investors.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.